Bone densitometry manufacturer Norland Medical Systems saw its second-quarter revenues more than double compared with the first quarter of this year, but sales were still lower than in the second quarter of 1997. The White Plains, NY, company enjoyed a
Bone densitometry manufacturer Norland Medical Systems saw its second-quarter revenues more than double compared with the first quarter of this year, but sales were still lower than in the second quarter of 1997. The White Plains, NY, company enjoyed a 135% second-quarter increase in revenue over first quarter of the year, with sales of $4.8 million. That figure, however, fell 6% short of the $5.1 million in sales that the company recorded in the second quarter of 1997.
Norland reported a net loss for the quarter of $1.5 million, compared with net income of $195,000 in the second quarter of 1997. Although revenues are still lower than last year's levels, the company said that sales are rebounding for both peripheral and axial dual-energy x-ray absorptiometer (DEXA) products. Norland also reported healthy demand for its new Apollo DXA peripheral scanner (SCAN 6/10/98), although that system was not released in time to contribute much to the company's second-quarter results. Norland executives say the firm has sold more Apollo systems since the product's introduction than any other of its peripheral units.
Norland's revenue rebound was overshadowed by a pending decision from the NASDAQ Stock Market's delisting hearing panel on the company's market eligibility. Norland has run afoul of the exchange's $4 million net tangible assets requirement. The company met with the delisting panel on July 29 and is awaiting a decision on its NASDAQ status.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.